ArticleESMO open2019

Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab.

Christopher Nevala-Plagemann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.